Benjamin A. Derman

1.7k total citations
80 papers, 636 citations indexed

About

Benjamin A. Derman is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Benjamin A. Derman has authored 80 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hematology, 35 papers in Oncology and 30 papers in Molecular Biology. Recurrent topics in Benjamin A. Derman's work include Multiple Myeloma Research and Treatments (50 papers), Protein Degradation and Inhibitors (21 papers) and CAR-T cell therapy research (13 papers). Benjamin A. Derman is often cited by papers focused on Multiple Myeloma Research and Treatments (50 papers), Protein Degradation and Inhibitors (21 papers) and CAR-T cell therapy research (13 papers). Benjamin A. Derman collaborates with scholars based in United States, Poland and Canada. Benjamin A. Derman's co-authors include Mary J. Fidler, Marta Batus, Philip Bonomi, Andrzej Jakubowiak, Kathryn F. Mileham, Jagoda Jasielec, Andrzej Jakubowiak, Satyajit Kosuri, Andrew Artz and Wei Zhang and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Benjamin A. Derman

62 papers receiving 633 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin A. Derman United States 13 297 280 216 101 72 80 636
Ankit Kansagra United States 15 361 1.2× 215 0.8× 207 1.0× 73 0.7× 48 0.7× 67 657
Florence Broussais France 14 350 1.2× 216 0.8× 347 1.6× 41 0.4× 85 1.2× 25 952
Stefanie Hieke Germany 9 250 0.8× 290 1.0× 195 0.9× 27 0.3× 81 1.1× 18 572
Monique Steijaert Netherlands 12 285 1.0× 281 1.0× 179 0.8× 62 0.6× 39 0.5× 13 615
Donald C. Moore United States 13 276 0.9× 144 0.5× 206 1.0× 45 0.4× 141 2.0× 80 750
Niels Frost Andersen Denmark 17 294 1.0× 371 1.3× 425 2.0× 31 0.3× 42 0.6× 42 756
Yesilda Balavarca Germany 19 487 1.6× 121 0.4× 275 1.3× 36 0.4× 195 2.7× 37 929
Sarah Bertoli France 19 216 0.7× 780 2.8× 449 2.1× 186 1.8× 72 1.0× 65 1.1k
Thomas E. Lew Australia 16 163 0.5× 211 0.8× 219 1.0× 54 0.5× 130 1.8× 33 880
Ghulam Rehman Mohyuddin United States 13 317 1.1× 342 1.2× 226 1.0× 51 0.5× 41 0.6× 129 629

Countries citing papers authored by Benjamin A. Derman

Since Specialization
Citations

This map shows the geographic impact of Benjamin A. Derman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin A. Derman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin A. Derman more than expected).

Fields of papers citing papers by Benjamin A. Derman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin A. Derman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin A. Derman. The network helps show where Benjamin A. Derman may publish in the future.

Co-authorship network of co-authors of Benjamin A. Derman

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin A. Derman. A scholar is included among the top collaborators of Benjamin A. Derman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin A. Derman. Benjamin A. Derman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morgan, Hywel, Benjamin A. Derman, H. Ma, & Shaji Kumar. (2025). Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias. Frontiers in Immunology. 16. 1558275–1558275. 2 indexed citations
2.
Landgren, Ola, Noa Biran, Elizabeth O’Donnell, et al.. (2025). Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma. HemaSphere. 9(7). e70178–e70178.
3.
Derman, Benjamin A. & Rafaël Fonseca. (2024). Measurable Residual Disease and Decision-Making in Multiple Myeloma. Hematology/Oncology Clinics of North America. 38(2). 477–495. 12 indexed citations
4.
Derman, Benjamin A., Jennifer H. Cooperrider, Tadeusz Kubicki, et al.. (2024). Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).. Journal of Clinical Oncology. 42(16_suppl). 106–106. 2 indexed citations
5.
6.
Derman, Benjamin A., Ajay Major, Jennifer H. Cooperrider, et al.. (2024). Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer Journal. 14(1). 10 indexed citations
7.
Kubicki, Tadeusz & Benjamin A. Derman. (2024). OA-17 Liquid Chromatography Mass Spectrometry (LC-MS) for Identification of Exceptional Responders in Newly Diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma Myeloma & Leukemia. 24. S11–S12.
8.
Jakubowiak, Andrzej, et al.. (2024). Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. The Oncologist. 29(9). 806–810. 1 indexed citations
9.
Derman, Benjamin A., et al.. (2024). Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data. PubMed. 1(1). 100003–100003. 1 indexed citations
10.
11.
Derman, Benjamin A., Ajai Chari, Jeffrey A. Zonder, et al.. (2023). A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. European Journal Of Haematology. 110(5). 564–570. 7 indexed citations
12.
Derman, Benjamin A., Jennifer H. Cooperrider, Jacalyn Rosenblatt, et al.. (2023). Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT). Blood. 142(Supplement 1). 4747–4747. 3 indexed citations
13.
Mohyuddin, Ghulam Rehman, Rajshekhar Chakraborty, Edward R. Scheffer Cliff, & Benjamin A. Derman. (2023). Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine. 65. 102272–102272. 7 indexed citations
14.
Jakubowiak, Andrzej, et al.. (2023). Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.. Journal of Clinical Oncology. 41(16_suppl). 6574–6574. 1 indexed citations
15.
Rouhani, Sherin J., Jovian Yu, Daniel J. Olson, et al.. (2022). Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. Journal for ImmunoTherapy of Cancer. 10(6). e004766–e004766. 8 indexed citations
16.
Wang, Bei, Benjamin A. Derman, Julie A. Johnson, et al.. (2022). Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. Cancers. 14(21). 5331–5331. 6 indexed citations
17.
Rojek, Alexandra E., Justin Kline, Daniel Appelbaum, et al.. (2021). Impact of Pre-Treatment Whole-Body Metabolic Tumor Volume on Toxicities and Outcomes in Patients Treated with Anti-CD19 CAR T-Cell Therapy for Aggressive Large B-Cell NHL. Transplantation and Cellular Therapy. 27(3). S193–S194. 1 indexed citations
18.
Kanelidis, Anthony, Francis J. Alenghat, Nitasha Sarswat, et al.. (2021). ATTR Cardiomyopathy Meets Multiple Myeloma. JACC CardioOncology. 3(4). 598–601. 6 indexed citations
19.
Derman, Benjamin A., et al.. (2020). Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer Journal. 10(8). 80–80. 40 indexed citations
20.
Derman, Benjamin A., Jochen Reiser, Sanjib Basu, & Agne Paner. (2018). Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma. International Journal of Nephrology. 2018. 1–6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ankit Kansagra Breakdown of academic impact, for papers by Florence Broussais Breakdown of academic impact, for papers by Stefanie Hieke Breakdown of academic impact, for papers by Monique Steijaert Breakdown of academic impact, for papers by Donald C. Moore Breakdown of academic impact, for papers by Niels Frost Andersen Breakdown of academic impact, for papers by Yesilda Balavarca Breakdown of academic impact, for papers by Sarah Bertoli Breakdown of academic impact, for papers by Thomas E. Lew Breakdown of academic impact, for papers by Ghulam Rehman Mohyuddin
Rankless by CCL
2026